The Role of Erythrocyte Sedimentation Rate (ESR) in Myeloproliferative and Lymphoproliferative Diseases: Comparison between DIESSE CUBE 30 TOUCH and Alifax Test 1

被引：4
作者：
Pelagalli, Martina [1 ,2 ]
Tomassetti, Flaminia [1 ,2 ]
Nicolai, Eleonora [1 ]
Giovannelli, Alfredo [1 ,2 ]
Codella, Silvia [1 ,2 ]
Iozzo, Mariannina [2 ]
Massoud, Renato [1 ,2 ]
Secchi, Roberto [3 ]
Venditti, Adriano [3 ]
Pieri, Massimo [1 ,2 ]
Bernardini, Sergio [1 ,2 ]
Hatzimichael, Eleftheria
机构：
[1] Univ Roma Tor Vergata, Dept Expt Med, Via Montpellier 1, I-00133 Rome, Italy
[2] Tor Vergata Univ Hosp, Dept Lab Med, Viale Oxford 81, I-00133 Rome, Italy
[3] Univ Tor Vergata, Dept Biomed & Prevent, Hematol, I-00133 Rome, Italy
来源：
DISEASES | 2023年 / 11卷 / 04期
关键词：
ESR; lymphoproliferative diseases; myeloproliferative diseases; cancer; C-REACTIVE PROTEIN; EARLY RELAPSE; INFLAMMATION; SURVIVAL; CANCER; EVOLUTION; UTILITY;
D O I：
10.3390/diseases11040169
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
(1) Background: The erythrocyte sedimentation rate (ESR) is widely diffused in hematology laboratories to monitor inflammatory statuses, response to therapies (such as antibiotics), and oncologic diseases. However, ESR is not a specific diagnostic marker but needs to be contextualized and compared with clinical and other laboratory findings. This study aimed to investigate the performance of two automated instruments, namely the DIESSE CUBE 30 TOUCH (DIESSE, Siena, Italy) and the Alifax Test 1 (Alifax Srl, Polverara, Italy), in comparison with the gold standard, the Westergren method, in lymphoproliferative and myeloproliferative patients. (2) Methods: 97 EDTA samples were selected from the hematology department of Roma Tor Vergata Hospital and analyzed. Statistical analysis was applied. (3) A good correlation between CUBE 30 TOUCH and the gold standard was observed in the overall sample (R2 = 0.90), as well as in patients with lymphoproliferative diseases (R2 = 0.90) and myeloproliferative diseases (R2 = 0.90). The correlation between Test 1 and the gold standard was observed in the overall sample (R2 = 0.68), as well as in patients with lymphoproliferative diseases (R2 = 0.79) and myeloproliferative diseases (R2 = 0.53). (4) Conclusions: The CUBE 30 TOUCH appears to be a more trustworthy tool for evaluating ESR in these pathologies.
引用
收藏
页数：12
相关论文
共 53 条
  • [1] The Erythrocyte Sedimentation Rate and the C-reactive Protein Test
    Batlivala, Sarosh P.
    [J]. PEDIATRICS IN REVIEW, 2009, 30 (02) : 72 - 74
  • [2] Bien Ewa, 2004, Med Wieku Rozwoj, V8, P1081
  • [3] Bray Christopher, 2016, WMJ, V115, P317
  • [4] Brigden ML, 1999, AM FAM PHYSICIAN, V60, P1443
  • [5] The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
    Campo, Elias
    Jaffe, Elaine S.
    Cook, James R.
    Quintanilla-Martinez, Leticia
    Swerdlow, Steven H.
    Anderson, Kenneth C.
    Brousset, Pierre
    Cerroni, Lorenzo
    de Leval, Laurence
    Dirnhofer, Stefan
    Dogan, Ahmet
    Feldman, Andrew L.
    Fend, Falko
    Friedberg, Jonathan W.
    Gaulard, Philippe
    Ghia, Paolo
    Horwitz, Steven M.
    King, Rebecca L.
    Salles, Gilles
    San-Miguel, Jesus
    Seymour, John F.
    Treon, Steven P.
    Vose, Julie M.
    Zucca, Emanuele
    Advani, Ranjana
    Ansell, Stephen
    Au, Wing-Yan
    Barrionuevo, Carlos
    Bergsagel, Leif
    Chan, Wing C.
    Cohen, Jeffrey I.
    d'Amore, Francesco
    Davies, Andrew
    Falini, Brunangelo
    Ghobrial, Irene M.
    Goodlad, John R.
    Gribben, John G.
    Hsi, Eric D.
    Kahl, Brad S.
    Kim, Won-Seog
    Kumar, Shaji
    LaCasce, Ann S.
    Laurent, Camille
    Lenz, Georg
    Leonard, John P.
    Link, Michael P.
    Lopez-Guillermo, Armando
    Mateos, Maria Victoria
    Macintyre, Elizabeth
    Melnick, Ari M.
    [J]. BLOOD, 2022, 140 (11) : 1229 - 1253
  • [6] CLINICAL STAGE-I AND HODGKIN STAGE-II DISEASE - A SPECIFICALLY TAILORED THERAPY ACCORDING TO PROGNOSTIC FACTORS
    CARDE, P
    BURGERS, JMV
    HENRYAMAR, M
    HAYAT, M
    SIZOO, W
    VANDERSCHUEREN, E
    MONCONDUIT, M
    NOORDIJK, EM
    LUSTMANMARECHAL, J
    TANGUY, A
    DEPAUW, B
    COSSET, JM
    CATTAN, A
    SCHNEIDER, M
    THOMAS, J
    MEERWALDT, JH
    SOMERS, R
    TUBIANA, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (02) : 239 - 252
  • [7] Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries
    Chaparro, Camila M.
    Suchdev, Parminder S.
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2019, 1450 (01) : 15 - 31
  • [8] Clinical biomarkers in sickle cell disease
    Damanhouri, Ghazi A.
    Jarullah, Jummanah
    Marouf, Samy
    Hindawi, S. I.
    Mushtaq, Gohar
    Kamal, Mohammad A.
    [J]. SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2015, 22 (01) : 24 - 31
  • [9] DINANT GJ, 1991, BRIT J GEN PRACT, V41, P365
  • [10] Dotson J.L., 2023, Myelodysplastic Syndrome
123456